Multidrug-resistant Enterobacterales infections in abdominal solid organ transplantation |
| |
| Affiliation: | 1. Centre d''infectiologie Necker-Pasteur, Hôpital Necker Enfants-Malades, Centre médical de l''institut Pasteur, Université de Paris, Paris, France;2. Équipe mobile de microbiologie Clinique, Groupe Hospitalier Paris Saint Joseph, Paris, France;3. Institut Micalis, UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Chatenay-Malabry, France;4. Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP.Nord, Université de Paris, Paris, France;5. Inserm UMR S1149, Centre de recherche sur l''inflammation;6. Departement of Nephrology-Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France;7. Service de Microbiologie Clinique et Plateforme de dosage des anti-infectieux, Groupe Hospitalier Paris Saint Joseph, Paris, France;8. Department of Medicine and Surgery, University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy;9. Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia;10. National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia;11. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia;12. Transplant Infectious Diseases Unit, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland;13. IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France;14. Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France |
| |
| Abstract: | BackgroundTransplant recipients are highly susceptible to multidrug-resistant (MDR) related infections. The lack of early appropriate antimicrobial treatment may contribute to the high mortality due to MDR-related infections in transplant recipients especially in case of metallo-β-lactamases.ObjectivesIn this review, we present the current state of knowledge concerning multidrug-resistant Gram negative bacilli's risk management in the care of solid-organ transplant recipients and suggest control strategies.SourcesWe searched for studies treating MDR g-negative bacilli related infections in the renal and hepatic transplant patient population. We included randomized and observational studies.ContentSolid-organ transplant is the best therapeutic option for patients diagnosed with end-stage organ disease. While the incidence of opportunistic infections is decreasing due to better prevention, the burden of “classical” infections related to MDR bacteria especially related to Gram-negative bacteria is constantly increasing.Over the last two decades, various MDR pathogens have emerged as a relevant cause of infection in this specific population associated with significant mortality. Several factors related to the management of transplant donor candidates and recipients increase the risk of MDR infections in transplant recipients. The awareness of this high susceptibility of transplant recipients to MDR-related infections challenges the choice of empirical therapy, while its appropriateness can only be validated a posteriori. Indeed, the lack of early appropriate antimicrobial treatment may contribute to the high mortality due to MDR-related infections in transplant recipients especially in case of metallo-β-lactamases.ImplicationsMultidrug-resistant Gram-negative bacteria are associated with high morbidity and mortality in solid organ transplant recipients. It seems important to identify patients at risk of colonization/MDR bacteria to evaluate strategies to limit the risk of secondary infections and to minimize the inappropriate use of broad-spectrum antibiotics. |
| |
| Keywords: | Carbapenemase Enterobacterales Extended-spectrum beta-lactamase Multidrug resistant Solid organ transplant |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
